American Healthcare Capital is pleased to present a developmental stage biopharmaceutical company that is pioneering and developing a conceptually new class of medical drug based upon proprietary methods of isotope-selective modulation of the human immune system. Based upon the results of pre-clinical studies, they believe their future products will be first-in-class therapeutic drugs enabling eradication and prevention of primary and metastatic cancers.

To date they have attained a proof-of-concept through research in cooperation with eight external academic institutions. They have a Patent-Protected IP portfolio that includes discoveries in mathematics, physics, chemistry, and life sciences. Currently, 6 Patents have been granted and 14 are Patent Pending. Phase I IRB has been conducted abroad with plans to enter Phase II in the United States.

While they are pre-revenue, their pipeline includes treatments for metastatic melanoma, pancreatic cancer and breast cancer all in the IND-enabling stage.

The owners are open selling a percentage of the company and/or the technology associated with one of the specific type of cancers above. They are open to discussing current valuation and price.

If you would like to learn more, please use the link on the right-hand side of the page to execute our NDA. You will need to copy the Listing Code (Example: TXMC1A) and Listing Title (Example: $1 Million Home Health Agency in Texas) from the summary above to complete the NDA.